Advertisement

Companion diagnostics and liquid biopsy

  • Frauke Adams
  • Jörg-M. Hollidt
  • Christof Winter

Abstract

The chapter describes potential POCT applications for companion diagnostics and liquid biopsy. Companion diagnostics are in-vitro methods, which provide information about the suitability and effectiveness of a particular therapeutic drug for a patient prior to its administration. It therefore allows stratification of patient populations. The term “liquid biopsy” or “liquid profiling” describes the analysis of tumor cells or free nucleic acids in blood and other body fluids, i.e. the urine of oncology patients. POCT shortens the time and spatial distance between diagnostics and therapy induction. In the future, near-patient companion diagnostics could gain importance, most importantly for calculating therapeutic dose adjustments. POCT could moreover help make personalized healthcare more accessible to patients in isolated regions.

References

  1. 1.
    Allyse M, Minear MA, Berson E et al. (2015) Non-invasive prenatal testing: a review of international implementation and challenges. Int J Womens Health 7:113–126Google Scholar
  2. 2.
    Bissonnette L, Bergeron MG (2012) Infectious disease management through Point-of-Care personalized medicine Molecular Diagnostic Technologies. J Pers Med 2:50–70CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Diaz LA, Jr., Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32:579–586CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Douillard JY, Ostoros G, Cobo M et al. (2014) First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 110:55–62CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Green BJ, Saberi Safaei T, Mepham A et al. (2016) Beyond the capture of circulating tumor cells: Next-generation devices and materials. Angew Chem 55:1252–1265CrossRefPubMedGoogle Scholar
  6. 6.
    Lewis JM, Heineck DP, Heller MJ (2015) Detecting cancer biomarkers in blood: challenges for new molecular diagnostic and point-of-care tests using cell-free nucleic acids. Expert Rev Mol Diagn 15:1187–1200CrossRefPubMedGoogle Scholar
  7. 7.
    Lo YM, Chiu RW (2012) Genomic analysis of fetal nucleic acids in maternal blood. Annu Rev Genomics Hum Genet 13:285–306CrossRefPubMedGoogle Scholar
  8. 8.
    Rojanasantikul P, Pattrapornpisut P, Anuruckparadorn K et al. (2014) The performance of a point of care test for detection of anti-mutated citrullinated vimentin and rheumatoid factor in early rheumatoid arthritis. Clin Rheumatol 33:919–923CrossRefPubMedGoogle Scholar
  9. 9.
    Scott SA (2013) Clinical pharmacogenomics: opportunities and challenges at point of care. Clin Pharmacol Ther 93:33–35CrossRefGoogle Scholar
  10. 10.
    Sonnenberg A, Marciniak JY, Rassenti L et al. (2014) Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood. Clin Chem 60:500–509CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Willis JC, Lord GM (2015) Immune biomarkers: the promises and pitfalls of personalized medicine. Nat Rev Immunol 15:323–329CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Frauke Adams
    • 1
  • Jörg-M. Hollidt
    • 1
  • Christof Winter
    • 2
  1. 1.in.vent Diagnostica GmbHHennigsdorfGermany
  2. 2.Klinikum rechts der TU MünchenInstitut für Klinische Chemie und PathobiochemieMünchenGermany

Personalised recommendations